← All trials
NCT06381817
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2024
- Primary completion
- Mar 31, 2028
- Completion date
- Mar 31, 2028
- First posted
- Apr 24, 2024
- Last posted
- Apr 26, 2024
- Enrollment
- 146
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Soochow UniversityLead sponsor
- Soochow UniversityOfficial
- Soochow UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Southern Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.